Incorporation Of Neomycin-Nicotinamide Microemulsion in Emulgel for Enhanced Antibacterial Skin Therapy

This study focused on the development and evaluation of Emulgel formulations containing Neomycin and Nicotinamide for potential use in antibacterial skin therapy. Three formulations, F1, F2, and F3, were prepared using Carbopol 940, Carbopol 934, and Hydroxypropyl Methylcellulose (HPMC) as the base polymers, respectively. The formulations were characterized for λmax using UV spectroscopy, which identified the optimal wavelengths for Neomycin (270 nm) and Nicotinamide (262 nm). Calibration curves were established to facilitate accurate quantitative analysis of these active pharmaceutical ingredients (APIs). The physical properties of the emulgels, including pH, viscosity, Spreadability, and extrudability, were evaluated to ensure suitability for topical application. In vitro drug release studies demonstrated controlled release profiles for both APIs. Particle size and zeta potential analyses confirmed the stability of the microemulsion systems within the emulgels. The antibacterial efficacy of the formulations was assessed against Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria. The results indicated significant antibacterial activity, especially for formulation F1, suggesting the potential of these emulgels in treating bacterial skin infections. Overall, the study successfully developed emulgel formulations with promising characteristics for topical drug delivery, combining effective drug release with desirable physical properties and significant antibacterial activity. These findings suggest the potential of these emulgels in providing effective skin therapy, particularly in bacterial infection treatments. Further research, including clinical evaluations, is recommended to fully establish their therapeutic potential and safety.